drugset / Trial / NCT00411268
Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this open-label, extension study is to characterize the safety, effectiveness, and impact on quality of life measures of long-term repeated dosing of OROS hydromorphone slow release (8, 16, 32 and 64 mg tablets) in patients with chronic low back pain.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2001-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydromorphone | Other / unclassified | 8 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 16 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 32 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 64 mg | Oral |
Indications
No indication recorded.